Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone versus placebo in overweight adults
ACTRN12606000313538Phase 3Completed
- Sponsor
- A/Prof PJ Manning
- Start
- Jan 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in obesity comparing Rosiglitazone with Placebo (2 arms). Primary endpoints: Oxidative stress markers and Insulin resistance. Started Jan 2003; status: completed.
02
Drugs
rosiglitazone
03
Conditions
obesity
Beyond the preview
Go deeper on ACTRN12606000313538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000313538.